siRNA and ASO are two nucleic acid-based gene silencing technologies that achieve precise regulation of gene expression by complementary pairing with specific mRNA sequences.
the Danish pharmaceutical company Zealand Pharma announced clinical Phase 1 data for its long-acting amylin analogue, Petrelintide, which is being studied for weight management.
RYBREVANT® (amivantamab-vmjw) with standard care now approved in the U.S. as the sole targeted treatment reducing disease progression risk by over 50% for second-line EGFR-mutated advanced lung cancer.
Sep 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Edgewise Therapeutics Reports Favorable Results from Phase 1 Study in Healthy Volunteers and Phase 2 CIRRUS-HCM Study in Obstructive Hypertrophic Cardiomyopathy Patients.